September 30, 2019 / 6:11 AM / 16 days ago

BRIEF-Addex Therapeutics H1 Net Profit Swings To Loss Of CHF 7.5 Mln

Sept 30 (Reuters) - ADDEX THERAPEUTICS LTD:

* DIPRAGLURANT PIVOTAL PHASE 2B/3 CLINICAL TRIAL ON TRACK TO DOSE FIRST PATIENT IN Q1 2020 AND READOUT TOPLINE RESULTS IN Q3 2021

* INCOME OF CHF1.2 MILLION IN FIRST-HALF 2019

* NET LOSS OF CHF7.5 MILLION IN FIRST-HALF 2019, COMPARED TO A NET INCOME OF CHF2.4 MILLION FOR FIRST-HALF 2018

* H1 TOTAL OPERATING LOSS CHF 7.5 MILLION VERSUS PROFIT CHF 2.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below